3499À­Ë¹Î¬¼Ó˹

ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

æÇÃÀGLP-1¶àëĹú¼ÊÃ÷ÐDzúÆ·£¡3499À­Ë¹Î¬¼Ó˹¶àëÄÐÂÒ©ÔÚ·ÊÅÖÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÐÂÍ»ÆÆ

ÈÕÆÚ£º

2026Äê04ÔÂ02ÈÕ 14:40


ÔÚ·ÊÅÖ¼°Ïà¹Ø´úлÐÔ¼²²¡³ÉΪȫÇòÐÔ½¡¿µÌôÕ½µÄµ±Ï£¬3499À­Ë¹Î¬¼Ó˹£¨ÒÔϼò³Æ“3499À­Ë¹Î¬¼Ó˹”£©´«À´Õñ·ÜÈËÐĵÄÏûÏ¢£¡Æä×ÔÖ÷Ñз¢µÄ´´ÐÂС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©£¬ÔÚÕë¶ÔDB/DB·ÊÅÖСÊóÄ£Ð͵ÄÁÙ´²Ç°Ñо¿ÖУ¬Õ¹ÏÖ³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõÖØÐ§¹û£»½áºÏÆä¶Ô¼¡ÈâµÄ±£³Ö×÷Óã¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷½Ú×÷Óã¬ÓÐÍû´øÀ´²îÒ컯µÄÁÙ´²Ñ¡Ôñ¡£

Ò»¡¢¾ªÑ޵ļõÖØÊý¾Ý

DB/DBСÊóÊÇÑо¿·ÊÅÖºÍ2ÐÍÌÇÄò²¡µÄ¾­µä¶¯ÎïÄ£ÐÍ£¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ÄÜȱÏÝ£¬±íÏÖ³öÑÏÖØµÄ·ÊÅÖ¡¢¸ßѪÌǺʹúлÎÉÂÒµÈÖ¢×´¡£ÔÚ3499À­Ë¹Î¬¼Ó˹¿ªÕ¹µÄÕâÏîÁÙ´²Ç°Ñо¿ÖУ¬¹«Ë¾×ÔÑеÄС·Ö×Ó»·ëÄÕ¹ÏÖ³öÓÅÒìµÄ¼õÖØÐ§¹û¡£

ÊÔÑé½á¹ûÏÔʾ£¬¾­¹ýΪÆÚ8ÖܵÄÖÎÁÆ£¬Óë¿Õ°×¶ÔÕÕ×éDB/DBСÊóÏà±È£¬MCR»·ëĽϸ߼ÁÁ¿×éµÄСÊóµÄÌåÖØÏ½µ·ù¶ÈԼΪGLP-1¶àëÄ×éµÄ1.25±¶£¬Ê¹DB/DBСÊóµÄÌåÖØÔö³¤Ç÷ÊÆÃ÷ÏÔ·Å»º£¬½Ó½ü½¡¿µ¶ÔÕÕ×éˮƽ¡£

 

c8b77f12-0cf6-4a72-b0dc-d6a3a99dfdb2

 

¶þ¡¢¶àÏî´úлָ±êÈ«Ãæ¸ÄÉÆ

MCR»·ëĽϸ߼ÁÁ¿×éÔÚ¸ÄÉÆ¸ÊÓÍÈýõ¥£¨TG£©¡¢¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼£¨HDL-C£©¡¢ÑªÌÇ¡¢ÄòÌÇˮƽ·½Ã棬ͬÑù±íÏÖÓÅÒ죺

1.TGˮƽ£ºÏÔÖø½µµÍDB/DBСÊóµÄTGˮƽ£¬ÓÅÓÚGLP-1¶àëÄ×飻

2.HDL-Cˮƽ£ºÃ÷ÏÔÉý¸ß£¬ÓÅÓÚGLP-1¶àëÄ×飻ÓÐÖúÓÚ½µµÍ¶¯ÂöÖàÑùÓ²»¯·çÏÕ£»

3.ѪÌÇˮƽ£ºÖÎÁÆ6ÖܵĽµµÍѪÌÇŨ¶ÈˮƽÓëGLP-1¶àëÄ×é½Ó½ü£»

4.ÄòÌÇˮƽ£ºÖÎÁÆ8Öܽ«ÄòÌÇˮƽ´Ó»ùÏß½µÖÁÒ»°ë£»

5.ÌÇ»¯Ñªºìµ°°×£¨HbA1c£©£ºÓëÄ£ÐÍ×éÏà±È£¬HbA1cϽµ·ù¶È´ïÔ¼1/3¡£

|ÁªºÏDZÁ¦

ÖµµÃÒ»ÌáµÄÊÇ£¬3499À­Ë¹Î¬¼Ó˹ÒÑ¿ªÕ¹ÁË»·ëÄÓëGLP-1ÀàÒ©ÎÈçGLP-1¶àëÄ£©ÁªºÏʹÓõÄÑо¿£¬½á¹ûÏÔʾÔÚÒûʳÓÕµ¼µÄ·ÊÅÖСÊóÄ£ÐÍÖУ¬Á½ÕßÔÚ¼õÖØÐ§¹û¼°¼¡Èâ±£»¤·½Ãæ¾ßÓÐÃ÷È·µÄЭͬЧӦ£º

1.Эͬ¼õÖØ£ºÁªºÏÓÃÒ©×é±íÏÖ³ö¸üÏÔÖøµÄ¼õÖØÐ§¹û£¬ÓÅÓÚµ¥Ò©ÖÎÁÆ£»

2.¼õÉÙ¼¡ÈâÁ÷ʧ£º»·ëÄÔÚÁªÓÃÖÐÓÐЧ»º½âGLP-1ÀàÒ©Îï´øÀ´µÄ¼¡ÈâÁ÷ʧÎÊÌ⣬Ìá¸ßÕûÌåÖÎÁư²È«ÐÔ¡£

Èý¡¢¶à°ÐµãЭͬ×÷Ó㺻·ëĵĴ´Ð»úÖÆ

MCR»·ëÄÖ®ËùÒÔÄܹ»ÔÚ¼õÖØ¼°ÆäËû´úлָ±êÉÏÈ¡µÃÈç´ËÓÅÒìµÄ³É¼¨£¬ÓëÆä¶ÀÌØµÄ×÷ÓûúÖÆÃܲ»¿É·Ö¡£×÷ΪһÖÖС·Ö×Ó»·ëÄÒ©ÎÄܹ»Í¬Ê±¾«×¼×÷ÓÃÓÚMC4RºÍMC1RÁ½¸ö¹Ø¼ü°Ðµã£¬Í¨¹ý¶à°ÐµãЭͬ×÷Ó㬷¢»ÓÆä׿ԽµÄ´úлµ÷½Ú¹¦Ð§¡£

|¼¤»îMC4R£ºÒÖÖÆÊ³Óû£¬´Ù½øÖ¬·¾·Ö½â

MC4RÊÇÖÐÊàÉñ¾­ÏµÍ³µ÷¿ØÄÜÁ¿Æ½ºâµÄ¹Ø¼üÊÜÌå¡£3499À­Ë¹Î¬¼Ó˹MCR»·ëÄ×÷ΪMC4R¼¤¶¯¼Á£¬Äܹ»´Ù½øÖ¬·¾·Ö½â£¬ÒÖÖÆÖ¬·¾Éú³É£»´Ù½ø°×ɫ֬·¾×éÖ¯ºÖ±ä£»Ìá¸ßÒȵºËØÃô¸ÐÐÔ£»ÔÚ²»ÏÔÖøÒÖÖÆÊ³ÓûµÄǰÌáÏÂʵÏÖ¼õÖ¬£¬±ÜÃâÑáʳ¸±×÷ÓÃ1¡£

 

528820a7-b432-4eb8-9319-127f44137ade

 

|¼¤»îMC1R:¿¹Ñ×ÃâÒßµ÷½Ú£¬»Ö¸´ÊÝËØÃô¸ÐÐÔ

MC1RÖ÷Òª²ÎÓëÃâÒßµ÷½ÚºÍÑ×Ö¢·´Ó¦¡£Í¨¹ý¼¤»îMC1R£¬Äܹ»ÏÔÖø¸ÄÉÆÌåÄÚÑ×֢΢»·¾³£¬½µµÍÑ×Ö¢Òò×Ó£¨°üÀ¨IL-1, TNF-a, IL-6, IL-8, and IL-12, iNOSµÈ£©µÄ±í´ï´Ó¶ø»Ö¸´ÊÝËØÃô¸ÐÐԺ͵÷½ÚÃâÒß·´Ó¦£¬¶Ô×ÔÉíÃâÒßÐÔ¼²²¡¾ßÓÐDZÔÚÖÎÁƼÛÖµ2¡£

2e9e4ae7-cbd8-4c9e-81e8-a16269e2f9a9

ËÄ¡¢¹ãÀ«µÄÓ¦ÓÃǰ¾°£º´úлÎÉÂÒÓë×ÔÉíÃâÒßÊÊÓ¦Ö¢

»ùÓÚMCR»·ëÄÔÚÁÙ´²Ç°Ñо¿ÖÐÕ¹ÏÖ³öµÄ׿Խ¼õÖØÐ§¹ûºÍ¶àϵͳ´úл¸ÄÉÆ×÷Óã¬3499À­Ë¹Î¬¼Ó˹¶ÔÆäδÀ´ÔÚ´úлºÍ×ÔÃâÁìÓòÖеÄÓ¦ÓÃǰ¾°³äÂúÐÅÐÄ¡£

´úл×ÛºÏÕ÷¼°Æä²¢·¢Ö¢·½Ã棬MCR»·ëIJ»½öÄܼõÖØ£¬»¹ÄÜͬ²½¸ÄÉÆÑªÌÇ¡¢ÑªÖ¬¡¢HbA1c¡¢ÄòÌǵȶàÏîÖ¸±ê£¬¶Ô2ÐÍÌÇÄò²¡¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡¡¢¸ßѪѹ¡¢¶¯ÂöÖàÑùÓ²»¯µÈ´úл×ÛºÏÕ÷×é·ÖÖ®Ò»»ò¶àÏî¾ßÓиÉԤDZÁ¦¡£

×ÔÉíÃâÒßÓëÑ×Ö¢Ïà¹Ø¼²²¡·½Ã棬ÓÉÓÚÆä¾ß±¸ÏÔÖøµÄ¿¹Ñ׺ÍÃâÒßµ÷½Ú×÷Óã¬Î´À´ÓÐÍûÍØÕ¹ÖÁÀà·çʪÐԹؽÚÑ×£»ÂýÐÔÉö²¡£¨CKD£©£»ÌÇÄò²¡Éö²¡£¨DN£©µÈÊÊÓ¦Ö¢¡£

½ÓÏÂÀ´£¬¹«Ë¾½«¼ÌÐøÍÆ¶¯¶àëÄÐÂÒ©µÄÁÙ´²Ç°Ò©ÀíѧºÍ¶¾ÀíѧÑо¿£¬ÕùÈ¡ÔçÈÕ½«ÐÂÒ©ÍÆÏòÁÙ´²½×¶Î£¬ÔÚÒÑÊÚȨµÄרÀû¼Ó³ÖÏ£¬¿ìËÙ½«²îÒ컯µÄºÃÒ©´ø¸øÓµÓÐÏà¹ØÖÎÁÆÐèÇóµÄ»¼ÕßȺÌå¡£

ÎÄÕÂÀ´Ô´ÓÚҩʱ´ú¹«ÖÚºÅ

²Î¿¼ÎÄÏ×

1. Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022). Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal transduction and targeted therapy, 7(1), 298.https://doi.org/10.1038/s41392-022-01149-x

2. Mun, Y., Kim, W., & Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. International journal of molecular sciences, 24(15),12152. https://doi.org/10.3390/ijms241512152

Ïà¹ØÍÆ¼ö

¡¾ÍøÕ¾µØÍ¼¡¿